View in EDS HTML Full Text PDF Full Text

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.

Saved in:
Bibliographic Details
Title: Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
Authors: Lim SM; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Yang SD; Department of Cyber Security & AI Technology, Kyung Hee Cyber University, Seoul, Republic of Korea., Lim S; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Heo SG; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Daniel S; Translational Science, Oncology R&D, AstraZeneca, Boston, MA, USA., Markovets A; Translational Science, Oncology R&D, AstraZeneca, Boston, MA, USA., Minoo R; Translational Science, Oncology R&D, AstraZeneca, Boston, MA, USA., Pyo KH; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Yun MR; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Hong MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, Republic of KoreaYonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Source: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2022 Feb 26; Vol. 14, pp. 17588359221079125. Date of Electronic Publication: 2022 Feb 26 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35251316
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lim+SM%22">Lim SM</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yang+SD%22">Yang SD</searchLink>; Department of Cyber Security & AI Technology, Kyung Hee Cyber University, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lim+S%22">Lim S</searchLink>; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Heo+SG%22">Heo SG</searchLink>; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Daniel+S%22">Daniel S</searchLink>; Translational Science, Oncology R&D, AstraZeneca, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Markovets+A%22">Markovets A</searchLink>; Translational Science, Oncology R&D, AstraZeneca, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Minoo+R%22">Minoo R</searchLink>; Translational Science, Oncology R&D, AstraZeneca, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pyo+KH%22">Pyo KH</searchLink>; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yun+MR%22">Yun MR</searchLink>; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Hong+MH%22">Hong MH</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+HR%22">Kim HR</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cho+BC%22">Cho BC</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, Republic of KoreaYonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101510808%22">Therapeutic advances in medical oncology</searchLink> [Ther Adv Med Oncol] 2022 Feb 26; Vol. 14, pp. 17588359221079125. <i>Date of Electronic Publication: </i>2022 Feb 26 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage%22">Sage </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101510808 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1758-8340 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217588340%22">17588340 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Med Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35251316
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/17588359221079125
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 17588359221079125
    Titles:
      – TitleFull: Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lim SM
      – PersonEntity:
          Name:
            NameFull: Yang SD
      – PersonEntity:
          Name:
            NameFull: Lim S
      – PersonEntity:
          Name:
            NameFull: Heo SG
      – PersonEntity:
          Name:
            NameFull: Daniel S
      – PersonEntity:
          Name:
            NameFull: Markovets A
      – PersonEntity:
          Name:
            NameFull: Minoo R
      – PersonEntity:
          Name:
            NameFull: Pyo KH
      – PersonEntity:
          Name:
            NameFull: Yun MR
      – PersonEntity:
          Name:
            NameFull: Hong MH
      – PersonEntity:
          Name:
            NameFull: Kim HR
      – PersonEntity:
          Name:
            NameFull: Cho BC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 02
              Text: 2022 Feb 26
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 1758-8340
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Therapeutic advances in medical oncology
              Type: main
ResultId 1